Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.

[1]  B. Slomovitz,et al.  Immunotherapy in endometrial cancer , 2023, International Journal of Gynecological Cancer.

[2]  A. Awada,et al.  Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. , 2022, European journal of cancer.

[3]  A. Tinker,et al.  Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.

[4]  V. Moreno,et al.  Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study , 2021, International Journal of Gynecological Cancer.

[5]  I. Vergote,et al.  Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). , 2021, Gynecologic oncology.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  Cyrus Chargari,et al.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.

[8]  I. Ray-Coquard,et al.  Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Talhouk,et al.  Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.

[10]  I. Vergote,et al.  Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. , 2015, Gynecologic oncology.

[11]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[12]  Juan A. Bueren-Calabuig,et al.  PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity , 2010, British journal of pharmacology.

[13]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.